Chris Hall: Yes. So we are seeing NeXT Dx, being ordered with next personal in our early access clients and that demand is strong. What we’re seeing in the marketplace and I think everyone has seen in the marketplace. Is that the power of the MRD testing is unique differentiated and the CGP testing positions are seeing more in a way that they’re more interchangeable, and so they’re ordering the CGP test paired with the MRD as a convenience, play, same patient, same tissues, same, etcetera. And so we’re certainly seeing that Tempus has their own MRD test. And so through the samples not MRD test their own CGP test excuse me and so they will be providing that now like they do with their customers. And so we expect the NeXT Dx, our approach to only come through with the doctors that we sell ourselves.
Thomas Flaten: Got it. Appreciate taking the question. Thank you.
Operator: The next question comes from Mike Mattson with Needham. Please go ahead.
Mike Mattson: Hey, Chris here and this is Joseph on from Mike. Maybe just one on pharma demand, obviously as you guys said, it’s seeing the increase in demand, there’s that mainly coming from, I guess new customers coming back in or is more existing customers kind of expanding their order books?
Chris Hall: Maybe just the similar customers that we’ve had up to now, so it’s not really new customers, it’s just the expansion of the order book and the opportunity. In addition, the maternal relationship has been strong and that business has started to increase as well.
Mike Mattson: And the next first moment, we basically have, the new use of ImmunoID and PCB is really starting to accelerate the market as Moderna enroll the patients in their clinical trials and then NeXT Personal being a new product. And the biopharma, starting to grow and so those, those two things are really starting to put ones to our sales relative to financial performance.
Mike Mattson: Yeah, Okay. Got it. And then maybe just in there for the Early access program for next personal, I guess, do you have a I guess an engagement rate for those using NeXT Dx and then I guess was that a full quarter that you guys kind of launched NeXT Dx?
Chris Hall: Yes. So, NeXT Dx, we launched, I would say a 1.5 years ago. And we kept it very, very, very small and it was used by a few physicians. When we launched NeXT Personal as an LDT laboratory developed test in October. That’s when we started to see NeXT Personal will be used side-by-side with, or, the NeXT Dx, the CGP product be used with the MRD product side-by-side. And I think I mean I will have to check, but the adoptions been wide across the entire 10 people in the AP program [ph]. I don’t know if I can say they have all done that, but certainly this significant majority, most of them have been using NeXT Dx at the same time that they use NeXT Personal.
Mike Mattson: Okay. And then just maybe one last one, for the molecular or I guess for the physicians in the quarter, I guess for the test, is there an average test per patient that you guys are seeing?
Chris Hall: I don’t think we have enough time to – I think we need more time to pass about an average test per patient, because I think a lot of these people are new. But we are starting to see the repeat testing and in fact, because when you are fixed at 10 physicians, a lot of times in these hyper growth modes in these companies launches, you are also – you are starting to really sign up a lot of new doctors and so your V1s are always growing at a dramatic rate, because you are growing into more doctors in the world where we fix the doctors. We have launched into rhythm and beat of getting the clinical samples coming from those doctors. Now, we have hit the point where the repeat testing is starting to outpace the weekly, new tests coming in, right, just because it’s starting to accelerate.
So, we will come up with a way that we ultimately talk about that metric. But I don’t think we have any insight right now, relative to the number of tests per patient. But I think as we get a year, 2 years in the rear view mirror, even when you start to look at it.
Mike Mattson: Got it. Okay. Yes. Thank you very much for taking our questions and congrats on the quarter.
Chris Hall: Thanks for being on.
Operator: The next question comes from Arthur He with H.C. Wainwright. Please go ahead.
Arthur He: Hi. Good afternoon Chris and Aaron. This is Arthur of RK. So, I guess I just wanted to get a quick question regarding the early access program for the Personal and Dx. For these programs for I know you mentioned that a doctor on the waiting list at the beginning, I am just curious is there any more doctors getting on the waiting list, is they getting longer, or and it was…?
Chris Hall: Hi. There was growth there, yes, we were. There has been growth and “waiting list”. We just decided we are not going to like track that quarter-over-quarter. We thought that the reported test was the best way to sort of provide insight. But we do have a wait list and then Tempest is starting their discussions. And so we expect there to be a pent-up demand that they are creating to separately as they engage with customers and discussions.
Arthur He: Got it. Thanks for the addition color. And regarding the reimburse application, you guys mentioned the aim for the trying to get to the four or three indications down this year. Besides the data package you prepare for that, what are other things you guys prepare to can increase the chance for getting the reimbursement approved?
Chris Hall: Yes, great question. So, the key thing is the data package. Now, one of the things that happened to us earlier in this quarter is that the analytics, analytical validation data which looked really, really strong was published. And that is the backbone of every one of the submissions that the test gives an answer across multiple cancer types. Now, the one part per million, it does that with really high specificity and so that’s like the backbone of every submission. Whenever you do this, the analytic validation data and this was really strong, really robust and a lot of studies, a lot of work that went into it. And we are really proud of it and super excited that it got published so quickly. So, that’s sort of the backbone of all three.
And then, we have to get clinical data in each one of these three. So, for lung cancer, early stage lung cancer, the work with TRACERx is key there. With breast cancer, the work with Royal Marsden is key there, because that’s multiple subtypes. But we are also working with Dana Farber. We are working with Ms. Kandari. Triple negative breast cancer patients, we have our own [Technical Difficulty] we have clinical trial. We are doing our cells called be stronger. Immunotherapy, we have got the UK data with Melanoma. We have got the Duke data with gastric patients and then we have got the large VHIO data. And so we continue to make progress running those samples. The key thing there is that collaborators will need to write the articles and they have to submit those articles.
And those articles have to be ultimately be accepted for us to drive the submissions. And so the one piece of this that is always difficult to predict is how long it takes collaborators to write articles and to submit articles, and ultimately for those articles to get articles to be to be accepted. But we have been very focused on driving this so that all of that comes together this year and that’s been our goal. And right now, we are on plan to accomplish that.
Arthur He: Awesome. Thanks for taking my question and congrats on the progress.
Chris Hall: Thanks Arthur.
Operator: This concludes our question-and-answer session as well as conference. Thank you for attending today’s presentation. You may now disconnect.
Chris Hall: Thanks.
